Shares of Viking Therapeutics surged as much as 40% premarket before settling around $37.10 (+23.2%) after the company reported that its experimental obesity injection kept weight off even when patients drastically reduced how often they took it. On the session, the stock swung between $31.00 and $45.92 — a wild range that underscores how much of Viking's value rides on a single drug that generates no revenue.

  • Patients Kept Nearly All Their Weight Loss With Half the Injections

In the 180-patient study, weekly dosing produced 16% to 19% body-weight reductions over 21 weeks, with an exploratory group reaching roughly 22% by Week 33 — and no plateau in sight. When patients switched to every-other-week shots for 12 more weeks, they maintained up to 97% of that loss; monthly shots preserved up to 90%, compared with just 61% for placebo.

Gastrointestinal side-effect rates during maintenance were similar to placebo — a critical detail because stomach issues are the top reason people quit these drugs.

  • Less Frequent Dosing Could Be Viking's Best Sales Pitch Against Giants The dominant obesity injection from Eli Lilly, tirzepatide (sold as Zepbound), requires weekly maintenance doses of 5 mg, 10 mg, or 15 mg indefinitely. If Viking can prove that patients only need a shot once or twice a month after an initial treatment phase, that convenience advantage could carve out meaningful market share. The results strengthen Viking's position in a market where companies are competing head-to-head with Eli Lilly and Novo Nordisk.

  • A $4 Billion Bet on a Company Burning Cash

At today's price, Viking's market cap sits around $4.37 billion with a negative P/E ratio of -6.46.

The company held $502 million in cash as of June 30 , funding two Phase 3 trials enrolling roughly 5,500 patients with data expected in 2027. Analysts assign a fair value near $93, implying the stock could still be deeply undervalued — but that math depends entirely on approval and commercial success years away.

  • The Next Test: Can a Pill Replace the Needle?

Viking is preparing to evaluate oral maintenance dosing in the next part of the study , and an oral formulation Phase 3 trial is expected to launch later this year. If an obesity pill works as well as the injection, the addressable patient pool expands dramatically. Today's data was a milestone, but Viking's real inflection point is still ahead.